



Fifth International Chordoma Research Workshop

Boston Marriott Cambridge Hotel, Salon 3

July 14–15, 2016

Wednesday, July 13

6:00 PM **CHECK-IN OPENS**

6:30 – 8:30 PM **WELCOME RECEPTION**

Thursday, July 14

7:00 AM **CHECK-IN AND CONTINENTAL BREAKFAST**

8:00 AM **WELCOME**

8:10 – 9:45 AM **SESSION I: STATE OF THE ART CARE**
Moderator: Shreyaskumar Patel, MD Anderson

8:15 AM Spine surgery
Laurence Rhines, MD Anderson

8:25 AM Skull base surgery
Zhen Wu, Beijing Tiantan Hospital

8:35 AM Particle therapy
Thomas DeLaney, Massachusetts General Hospital

8:50 AM Hypofractionated radiotherapy
Yoshiya (Josh) Yamada, Memorial Sloan Kettering

9:00 AM Systemic therapy
Silvia Stacchiotti, Istituto dei Tumori

9:10 AM Lightning poster presentations

9:20 AM Discussion
What are the greatest challenges and opportunities for improving the clinical management of chordoma?

9:45 AM **BREAK**

**10:00 AM –
12:00 PM**

SESSION II: CHORDOMA PATHOGENESIS

Moderator: Paul Meltzer, National Cancer Institute

10:05 AM

Rare germline variants in BRCA2 and PALB2 in familial and sporadic chordoma

Rose Yang, National Cancer Institute

10:25 AM

The genomic landscape of chordoma

Patrick Tarpey, Sanger Institute

10:45 AM

Epigenetic profiling reveals a unique histone code in chordoma

Nelson Moussazadeh, Memorial Sloan Kettering

11:05 AM

Emerging microRNAs (miRs) roles and strategies in chordoma

Zhenfeng Duan, Massachusetts General Hospital

11:25 AM

Lightning poster presentations

11:35 AM

Discussion

12:00 PM

LUNCH

Buffet lunch served in Salon 4

1:00 – 3:10 PM

SESSION III: DISEASE MODELS

Moderator: Adrienne Flanagan, University College London

1:00 PM

Establishment and characterization of chordoma cell lines as cell model systems

Thomas Barth, University of Ulm

1:20 PM

Establishment of patient derived chordoma xenograft models for in vivo testing: Opportunities and challenges

Gary Gallia, Johns Hopkins Medicine

1:40 PM

START-Chordoma Foundation preclinical collaboration: Establishment and evaluation of patient derived xenograft (PDX) and cell-based chordoma models

Michael Wick, START

2:00 PM

Lineage-directed expression of Brachyury induces chordoma in mice

Michael Kelley, Duke University

2:20 PM

Seeing cancer where it starts: modeling chordoma in zebrafish

Alexa Burger, University of Zurich

2:40 PM

Lightning poster presentations

2:50 PM

Discussion

3:10 PM **BREAK**

3:30 – 5:00 PM **SESSION IV: IMMUNOLOGY AND IMMUNOTHERAPY**
Moderator: Christopher Heery, National Cancer Institute

3:30 PM Primer on tumor immunology
Christopher Heery, National Cancer Institute

3:40 PM Why do we need to be interested in HLA Class 1 antigen
processing machinery component expression in chordoma?
Potential clinical relevance and results
Soldano Ferrone, Massachusetts General Hospital

4:00 PM Anti-PD-1 therapy for metastatic chordoma
Michael Lim, Johns Hopkins University

4:20 PM Immunogenic modulation of chordoma cells results in
enhanced immune cell killing: Foundation for combination
therapy clinical trials
James Hodge, National Cancer Institute

4:40 PM Discussion

5:00 – 5:15 PM **LIGHTNING POSTER PRESENTATIONS**

5:30 – 7:30 PM **RECEPTION AND POSTER VIEWING**
Hors d'oeuvres and cash bar in Salons 5–7

Friday, July 15

7:30 AM **CHECK-IN AND CONTINENTAL BREAKFAST**

8 – 10:45 AM **SESSION V: BRACHYURY BIOLOGY AND THERAPEUTIC
DEVELOPMENT**
Moderator: Joanne Kotz, Broad Institute

8:00 AM Brachyury expression and function in human carcinomas
Duane Hamilton, National Cancer Institute

8:20 AM Characterization of protein-protein interactions for brachyury
Ernest Radovani, University of Toronto

8:40 AM T-Brachyury reporter system for high-throughput screening
Slim Sassi, Massachusetts General Hospital

9:00 AM Discussion
9:15 AM Short break
9:25 AM Systematic identification of chordoma vulnerabilities
Tanaz Sharifina, Broad Institute
9:55 AM Developing therapies for transcriptionally addicted cancers
Nathanael Gray, Dana-Farber Cancer Institute
10:25 AM Discussion

10:45 AM BREAK

11:00 AM – 12:20 PM **SESSION VI: NOVEL TARGETS AND THERAPIES**
Moderator: Deric Park, National Cancer Institute

11:00 AM The role of TGFb3 in the pathogenesis of chordoma
Wei Chen, Beijing Institute of Genomics
11:15 AM The CDK4/CDK6 pathway as a target for growth inhibition of chordomas cell lines
Thomas Barth, University of Ulm
11:30 AM Novel protein phosphatase 2A inhibitor, LB100, sensitizes chordoma cells to irradiation
Shuyu Hao, National Cancer Institute
11:45 AM Afatinib: a promising therapeutic approach in chordoma
Paola Magnaghi, Nerviano Medical Sciences
12:00 PM Discussion

12:20 PM LUNCH
Group photo and buffet lunch in Salon 4

1:30 PM DISTINGUISHED TALK ON DRUG DEVELOPMENT
Glenn Dranoff, Novartis

2:15 PM PANEL DISCUSSION: FUTURE THERAPEUTICS
Moderator: Stuart Schreiber, Broad Institute

Glenn Dranoff, Novartis
Christoph Lengauer, Blueprint Therapeutics
Lilli Petruzzelli, Novartis

3:00 PM BREAK

3:15 – 4:40 PM	SESSION VII: CLINICAL TRIALS <i>Moderator: Christopher Heery, National Cancer Institute</i>
3:15 PM	Nivolumab + hypofractionated radiation trial <i>Michael Lim, Johns Hopkins Medicine</i>
3:25 PM	Yeast-brachyury vaccine trial <i>Christopher Heery, National Cancer Institute</i>
3:35 PM	c. Novyi trial <i>Mrinal Gounder, Memorial Sloan Kettering</i>
3:45 PM	Afatinib trial and SARCO trial <i>Silvia Stacchiotti, Istituto dei Tumori</i>
4:00 PM	Discussion: Lessons learned from chordoma trials

4:40 PM	BREAK
----------------	--------------

4:50 – 5:30 PM	SESSION VIII: NEXT FRONTIERS IN CHORDOMA RESEARCH <i>Moderator: Robert Schoelkopf, Yale University</i>
4:50 PM	Use of circulating tumor DNA as a biomarker for individuals with chordoma <i>Chetan Bettegowda, Johns Hopkins Medicine</i>
5:10 PM	Computing cancer: Applications for mathematical and computational modeling in cancer <i>Kimberly Luddy, Moffitt Cancer Center Imaging</i>

5:30 – 6:00 PM	GROUP REFLECTION AND WRAP UP <ul style="list-style-type: none"> ▪ <i>What are the most important questions that remain to be answered?</i> ▪ <i>What are the most promising opportunities to advance therapeutic development?</i>
-----------------------	--

6:00 PM	BREAK
----------------	--------------

6:30 – 9:00 PM	RECEPTION AND DINNER WITH PATIENT COMMUNITY <i>Salon Foyer and Salon 4</i>
-----------------------	--
